Rangwala, Reshma
Genmab (United States)
3 papers on CoChat
Most cited papers
- Verified
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 10,089
- Verified
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 6,198
- Verified
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology
Monoclonal and Polyclonal Antibodies ResearchLung Cancer Treatments and Mutations
Cited by 237
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free